Covaxin: Indigenous Vaccine for COVID-19
Covaxin is India's first vaccine candidate to have gone into human clinical trials. It is developed by Bharat Biotech and has been approved by the Drug Controller General of India (DCGI) for phase I and II human clinical trials.
- The SARS-CoV-2 strain was isolated in National Institute of Virology (NIV), Pune and transferred to Bharat Biotech. They developed Covaxin as an “inactivated” vaccine — one made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate. Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 The Services Sector as India’s Growth Multiplier: Challenges and Policy Pathways
- 2 India’s Clean Energy Leap: Opportunities, Obstacles & the Road to 2030
- 3 Decoding India’s Strategic Reset with Afghanistan
- 4 India, Mongolia Mark 70 Years of Diplomatic Ties
- 5 AI Roadmap for Inclusive Societal Development
- 6 India-Russia Relations: Celebrating Decades of Unwavering Trust
- 7 RTI at 20: Milestones, Challenges and the Road Ahead
- 8 India’s Biotech Surge: Powering Growth Through Science
- 9 Kautilya Economic Conclave 2025: Navigating India’s Path in a Fragmented Global Economy
- 10 Abolition of GST Compensation Cess: Concerns Over States’ Revenue & Fiscal Autonomy
